A lack of published research directly comparing the ALDH+ and CD44+/CD24- breast CSC populations in the context of patient tumor samples indicates an opportunity for further study to elucidate the mechanism of prostaglandin signaling in breast CSCs and the tumor microenvironment. The gene discussed is LDHA; the disease is neoplasm.